EMA/451374/2012

# European Medicines Agency decision

P/0144/2012

of 23 July 2012

on the acceptance of a modification of an agreed paediatric investigation plan for lopinavir / ritonavir (Kaletra) (EMEA-001005-PIP01-10-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Disclaimer**

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

# European Medicines Agency decision

P/0144/2012

of 23 July 2012

on the acceptance of a modification of an agreed paediatric investigation plan for lopinavir / ritonavir (Kaletra) (EMEA-001005-PIP01-10-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/199/2011 issued on 4 August 2011,

Having regard to the application submitted by Abbott Laboratories Limited on 19 April 2012 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 June 2012, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

***Article 1***

Changes to the agreed paediatric investigation plan for lopinavir / ritonavir (Kaletra), oral solution, soft capsules, film-coated tablets, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

***Article 2***

This decision is addressed to Abbott Laboratories Limited, Abbott House, Vanwall Business Park, Vanwall Road, SL6 4XE - Maidenhead, Berkshire, United Kingdom.

Done at London, 23 July 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/287994/2012

# Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001005-PIP01-10-M01

## Scope of the application

**Active substance(s):**

Lopinavir / ritonavir

**Invented name:**

Kaletra

**Condition(s):**

Treatment of human immunodeficiency virus (HIV-1) infection

**Authorised indication(s):**

See Annex II

**Pharmaceutical form(s):**

Oral Solution

Soft capsules

Film-coated tablets

**Route(s) of administration:**

Oral use

**Name/corporate name of the PIP applicant:**

Abbott Laboratories Limited

**Information about the authorised medicinal product:**

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
**Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
**E-mail** info@ema.europa.eu **Website** www.ema.europa.eu

## Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Abbott Laboratories Limited submitted to the European Medicines Agency on 19 April 2012 an application for modification of the agreed paediatric investigation plan with a waiver as set out in the European Medicines Agency's decision P/199/2011 issued on 4 August 2011.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 15 May 2012.

## Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified

## Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 8 June 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

# Annex I

# The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

# 1. Waiver

## *1.1. Condition: Treatment of human immunodeficiency virus (HIV-1) infection*

The waiver applies to:

- All subsets of the paediatric population from 2 to less than 18 years of age;
- for soft capsule, oral solution, and film-coated tablets for oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as the needs are already covered.

The waiver applies to:

- All subsets of the paediatric population from birth to less than 14 days of age;
- for soft capsule, oral solution, and film-coated tablets for oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

The waiver applies to:

- All subsets of the paediatric population from 14 days to less than 2 years of age;
- for soft capsule and film-coated tablets for oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit.

# 2. Paediatric Investigation Plan

## *2.1. Condition: Treatment of human immunodeficiency virus (HIV-1) infection*

### 2.1.1. Indication(s) targeted by the PIP

Treatment of human immunodeficiency virus (HIV-1) infection.

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 14 days to less than 2 years of age.

### 2.1.3. Pharmaceutical form(s)

Oral solution.

### 2.1.4. Studies

| Area | Number of studies | Description |
|---|---|---|
| Quality | 0 | Not applicable. |
| Non-clinical | 0 | Not applicable. |
| Clinical | 3 | **Study 1:**<br>Open-label, multicentre trial of lopinavir/ritonavir (LPV/r) based combination retroviral therapy in HIV-1 infected infants less than 6 months of age to evaluate pharmacokinetics and safety.<br>**Study 2:**<br>Open-label, randomised, non-inferiority, three arm, regimen-comparison, multicentre trial to evaluate whether early antiretroviral therapy given over a limited period of time in children from 6 weeks to less than 13 weeks of age, infected with HIV-1 would delay progression of disease compared to those treated when the immune system begins to decline.<br>**Study 3:**<br>Open label, randomized, multicentre trial to compare rates of treatment failure at 24 weeks in HIV-1 infected children from 6 to less than 37 months who have or have not been exposed to single-dose nevirapine (sdNVP) for prevention of mother-to-child transmission (PMTCT). |

# 3. Follow-up, completion and deferral of PIP

| | |
|---|---|
| Concerns on potential long term safety issues in relation to paediatric use: | Yes |
| Date of completion of the paediatric investigation plan: | By March 2013 |
| Deferral for one or more studies contained in the paediatric investigation plan: | No |

# Annex II

# Information about the authorised medicinal product

**Condition(s) and authorised indication(s):**

1. Treatment of human immunodeficiency virus (VIH-1) infection

   Authorised indications: Treatment of human immunodeficiency virus (HIV-1) in infected adults, adolescents and children above the age of 2 years, in association with other antiretroviral medicinal products

| EU Number | Invented name | Strength | Pharmaceutical form | Route of administration | Packaging | Content (concentration) | Package size |
|---|---|---|---|---|---|---|---|
| EU/1/01/172/001 | Kaletra | 133.3 /33.3 mg | Capsule, soft | Oral use | bottle (HDPE) | | 180 capsules |
| EU/1/01/172/002 | Kaletra | 133.3 /33.3 mg | Capsule, soft | Oral use | blister (PVC) | | 180 capsules |
| EU/1/01/172/003 | Kaletra | (80 mg + 20 mg) / ml | Oral solution | Oral use | bottle (PET) | 60 ml | 5 bottles + 5 x 5 ml syringes |
| EU/1/01/172/004 | Kaletra | 200 mg / 50 mg | Film-coated tablet | Oral use | bottle (HDPE) | | 120 tablets |
| EU/1/01/172/005 | Kaletra | 200 mg / 50 mg | Film-coated tablet | Oral use | blister (PVC) | | 120 tablets |
| EU/1/01/172/006 | Kaletra | 100 mg / 25mg | Film-coated tablet | Oral use | bottle (HDPE) | | 60 tablets |
| EU/1/01/172/007 | Kaletra | 200 mg / 50 mg | Film-coated tablet | Oral use | bottle (HDPE) | | 360 (3 x 120) tablets |
| EU/1/01/172/008 | Kaletra | 200 mg / 50 mg | Film-coated tablet | Oral use | blister (PVC) | | 120 (10 x 12) tablets |